There is increasing evidence supporting the use of preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
In an attempt to facilitate complete surgical resection with clear margins, Dr David Sebag-Montefiore and colleagues from England described their experience of using a 5-day per week regime of preoperative capecitabine chemo radiotherapy between 2004 and 2006.
|93% proceeded to macroscopically complete surgical resection|
|British Journal of Cancer|
The research team selected 70 patients with magnetic resonance imaging-defined locally advanced rectal cancer.
Capecitabine was given at a dose of 900 mg/m2 for 5 days per week combined with 45 Gy of radiotherapy in 25 doses.
The team found that this regime was well tolerated with 89% of patients receiving the full dose of chemotherapy.
The researchers reported that 96% received the full dose of radiotherapy.
The team found that 93% proceeded to macroscopically complete surgical resection.
The pathological complete response rate was 9% with a node-negative rate of 66%.
The research team observed that a negative circumferential margin was achieved by 79% of the patients who underwent resection.
Dr Sebag-Montefiore's team concluded, "Compared to studies using a 7-day per week capecitabine schedule, our results show increased compliance and less dose reductions with comparable pathological outcome."